drugset
drugset / Trial / NCT00872586

Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension

NCT00872586 ↗

Phase 3 Completed 304 enrolled Daiichi Sankyo Shanghai Sankyo Pharmaceuticals Co., Ltd. · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is designed to evaluate the additional efficacy and safety of olmesartan medoxomil/hydrochlorothiazide in the treatment of Chinese patients with mild to moderate essential hypertension, who fail to attain the blood pressure goals with olmesartan medoxomil monotherapy

Timeline

Start
2006-08
Primary completion
2007-07
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrochlorothiazide Unknown 12.5 mg Oral
Comparator Olmesartan medoxomil Unknown 20 mg Oral
Comparator Olmesartan medoxomil Unknown 40 mg Oral

Indications

essential hypertension